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Abstract
Background: Patients with prevalent or incident tuberculosis (TB) in antiretroviral treatment (ART) programmes in sub-
Saharan Africa have high mortality risk. However, published data are contradictory as to whether TB is a risk factor for
mortality that is independent of CD4 cell counts and other patient characteristics.
Methods/Findings: This observational ART cohort study was based in Cape Town, South Africa. Deaths from all causes were
ascertained among patients receiving ART for up to 8 years. TB diagnoses and 4-monthly CD4 cell counts were recorded.
Mortality rates were calculated and Poisson regression models were used to calculate incidence rate ratios (IRR) and identify
risk factors for mortality. Of 1544 patients starting ART, 464 patients had prevalent TB at baseline and 424 developed
incident TB during a median of 5.0 years follow-up. Most TB diagnoses (73.6%) were culture-confirmed. A total of 208
(13.5%) patients died during ART and mortality rates were 8.84 deaths/100 person-years during the first year of ART and
decreased to 1.14 deaths/100 person-years after 5 years. In multivariate analyses adjusted for baseline and time-updated risk
factors, both prevalent and incident TB were independent risk factors for mortality (IRR 1.7 [95% CI, 1.2–2.3] and 2.7 [95% CI,
1.9–3.8], respectively). Adjusted mortality risks were higher in the first 6 months of ART for those with prevalent TB at
baseline (IRR 2.33; 95% CI, 1.5–3.5) and within the 6 months following diagnoses of incident TB (IRR 3.8; 95% CI, 2.6–5.7).
Conclusions: Prevalent TB at baseline and incident TB during ART were strongly associated with increased mortality risk.
This effect was time-dependent, suggesting that TB and mortality are likely to be causally related and that TB is not simply
an epiphenomenon among highly immunocompromised patients. Strategies to rapidly diagnose, treat and prevent TB prior
to and during ART urgently need to be implemented.
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Introduction
HIV-associated tuberculosis (TB) remains a substantial
challenge to international public health, accounting for an
estimated 1.1 million new TB cases and 0.35 million deaths
worldwide in 2010 [1]. A staggering 82% of these cases and
71% of deaths were in sub-Saharan Africa [1]. This burden of
disease represents a particular challenge to antiretroviral
treatment (ART) programmes in the region as it is concentrated
in patients accessing these services [2,3]. Approximately 5–40%
of patients enrolling in ART services have a current TB
diagnosis at the time of starting ART [2–8]. In addition, there
is a high incidence of disease during the initial months of ART,
much of which represents prevalent disease present at baseline
that was not detected during screening. Long term rates are
lowered substantially during ART, but nevertheless remain
several fold higher than rates in HIV-uninfected people living in
the same communities [9].
Post-mortem studies from sub-Saharan Africa both before and
during the ART era have shown diagnosed and undiagnosed TB
to be extremely common among hospital in-patients dying with
HIV/AIDS, with disseminated disease being observed in 30%–
50% of cadavers [10–13]. However, it is not entirely clear whether
TB is causally related to death, a marker of HIV-associated
immunodeficiency that is not reflected by CD4 cell counts or is
simply an epiphenomenon among highly immunocompromised
patients [14]. TB has been reported as a leading cause of death in
ART programmes and yet attributing causes of death is difficult,
especially since multiple pathologies are so common. While many
studies agree that TB patients in ART programmes have high
mortality risk in unadjusted analyses, contradictory findings are
reported regarding whether TB is a risk factor for mortality that is
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independent of the baseline CD4 cell count and other patient
characteristics [5–8,15–18]. A meta-analysis of studies found no
such association but concluded that data were insufficient to draw
definite conclusions [19].
Many factors may explain the differences between study
findings. Widely used, non-culture-based TB diagnostics perform
poorly in this patient population, leading to considerable under-
diagnosis and some over-diagnosis. Thus, misclassification within
diseased and comparator groups may be important [20]. Most
patients with prevalent TB do not start ART until some weeks
after commencing TB treatment such that there is substantial
survival bias among those who subsequently start ART. Moreover,
most studies have simply assessed mortality with respect to baseline
patient characteristics and have not accounted for the rapid
changes in mortality risk that occur in association with time-
updated variables such as CD4 cell counts and plasma viral load
[21,22].
Identification of successful interventions to address the high
overall mortality in ART services in sub-Saharan Africa must be
based on careful identification of the underlying risk factors and
causes [23]. In this study, we therefore sought to assess the
association of prevalent and incident TB with mortality risk after
controlling for other risk factors, including age, duration of ART
and time-updated immunovirological responses to ART. In this
cohort in Cape Town, South Africa, culture-based diagnosis of TB
is routinely available and so a majority of disease is microbiolog-
ically proven. The duration of follow-up was prolonged and time-
updated CD4 cell counts and frequent viral load measurements
were made during follow-up.
Methods
Study Setting
This study was part of ongoing research at the ART service in
Gugulethu township, Cape Town, which has previously been
described [2,9,24]. Patients enrolled consecutively into the ART
programme from September 2002 until May 2006 were eligible
for the study. Patients were excluded if they did not initiate ART,
were non-naı¨ve to ART at enrolment due to transfer in from
another service and if aged less than 16 years. All other patients
were included in the analysis and data was censored on 1st January
2011, covering a period of over 8 years.
Programmatic criteria for starting ART followed national
guidelines, based on the 2002 WHO recommendations, providing
free ART for those with a CD4 cell count,200 cells/mL or World
Health Organization stage 4 disease [25]. Patients were referred
from other clinics to start ART and were routinely reviewed at
pre-treatment screening visits, treatment initiation, after 4, 8 and
16 weeks of ART, and at least every 4 months thereafter. Patients
had open access to the clinic at all other times. Blood CD4 cell
counts and plasma viral load levels were done routinely at baseline
and every 4 months. All patients were allocated to community-
based therapeutic counsellors for ongoing support, also providing
an efficient system for determining outcomes and tracing those
who did not attend follow-up appointments. Patients predomi-
nantly received efavirenz-based ART but did not receive isoniazid
preventive therapy (IPT) as was the practice at that time. All
patients received prophylaxis with trimethoprim-sulphamethoxa-
zole before and during ART.
Tuberculosis Screening, Diagnosis and Definitions
TB screening was conducted at baseline using a symptom-
screening questionnaire to identify patients who required further
investigation. Investigations available to diagnose TB at baseline
or during ART included sputum induction, sputum smear
fluorescence microscopy, automated liquid culture of sputum
using mycobacterial growth indicator tubes (MGIT 960, Becton
Dickinson, Sparks, Maryland, USA), chest radiology, ultrasonog-
raphy and fine needle lymph node aspiration and cytology. All
microbiological specimens were analysed in accredited laborato-
ries, and all positive cultures were speciated by polymerase chain
reaction.
‘Past history of TB’ was defined as a diagnosis of TB with
completion of anti-tuberculosis treatment before enrolment for
ART and was ascertained from referral letters and from
questioning patients. ‘Prevalent TB’ was defined as patients taking
anti-tuberculosis treatment at the time of starting ART. These
were TB diagnoses either made prior to referral for ART or
between screening and ART initiation. ‘Incident TB’ was defined
as a new clinical episode of TB diagnosed after initiation of ART
irrespective of date of symptom onset. Diagnoses of ‘recurrent TB’
were made with reference to any previous episodes of TB. Patients
with multiple diagnoses of incident TB had completed a full course
of anti-TB treatment with resolution of symptoms between
episodes, as ascertained from clinical records.
All cases of TB fulfilled WHO diagnostic criteria for resource-
constrained settings with high HIV prevalence [26]. Any culture-
negative TB diagnoses were defined by radiological abnormalities
consistent with active TB, strong histological or clinical evidence of
active TB and a clinician’s decision to treat with a full course of
anti-tuberculosis chemotherapy. TB treatment was rifampicin-
based and administered via a local network of community clinics
providing a directly observed treatment short-course strategy.
Data Collection and Ethics
Data on baseline characteristics and TB events was obtained
from prospectively maintained structured clinical records. Labo-
ratory results were transferred weekly to an electronic database.
Patient outcomes during ART were classified as follows: alive and
receiving ART, death from any cause, transfer to another ART
service, or lost to follow-up (LTFU). LTFU was defined as patients
on ART who were over 12 weeks late for a scheduled clinic
appointment, failed to return to the ART programme and could
not be located by active community-based follow-up. Data for
patients LTFU was censored at their last clinic visit. Deaths were
ascertained by hospital or medical records, discharge letters or by
active community-based follow-up by peer counsellors as previ-
ously described [27].
All patients enrolled in the study gave written, informed consent
to participate. The collection of data on this study cohort for
research purposes was approved by the Research Ethics Commit-
tee of the University of Cape Town.
Data Analysis
Data were analysed using Stata version 11.0 (College Station,
Texas, USA). Person-time was accrued from the date of starting
ART until death, transfer, LTFU or censoring of observations on
1st January 2011. Chi-squared tests were used for comparing
proportions, t-tests for comparing means and Wilcoxon rank-sum
tests for comparing medians. All statistical tests were two-sided at a
value of 0.05.
Person-time was divided into intervals predefined by the CD4
cell count measurements done at least 4-monthly. Each interval
was defined by the CD4 cell count and viral load at the start of the
interval, and categorised into CD4 cell count strata and viral load
strata. If CD4 cell count or viral load measurements were missing
for one or more intervals, a mean of the values for the preceding
and subsequent intervals were used (1.6% of intervals). Poisson
TB-Associated Mortality during ART
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regression models were used to calculate incidence rate ratios
(IRR) with 95% confidence intervals (CI) for time-updated and
baseline characteristics. Poisson regression was chosen to allow a
description of the effect of ART duration on mortality rates in
addition to controlling for it. Cross-tabulation and chi-squared
tests were used to assess associations between variables. A
multivariate model was constructed using Poisson regression and
based on forward selection; a priori risk factors (age and duration of
ART) and variables identified as being associated with incident TB
during the unadjusted analysis were included. Likelihood ratio
tests were used to investigate interactions between variables,
statistical hypotheses and linear trends.
Several exploratory analyses were also performed to better
understand which individuals were at greatest risk of mortality
during ART. These models stratified TB diagnoses by recurrent
disease, multiple TB diagnoses during ART, culture-confirmed
incident TB and by time following TB diagnosis. Poisson
regression was used along with aforementioned risk factors and
covariates.
Results
Patients Enrolled and Follow-up
During the study period, 2000 patients enrolled into the ART
programme. A total of 456 were excluded because they were aged
less than 16 years (n = 161), non-naı¨ve to ART (n = 85), died
before starting ART (n = 91) or deferred from starting ART for a
variety of reasons (n = 119) (Figure 1). 1544 (77.2%) initiated
ART and were included in the analysis. Of these patients, 208
(13.5%) died during ART, 318 (20.6%) were lost to follow-up and
207 (13.4%) were transferred to other ART services. Median
follow-up time for patients enrolled in the study was 5.0 years
(IQR 2.4–5.4; range 0.0–8.2).
The mean age was 34 years, and the majority of patients were
women (70.1%). Overall, patients had advanced immunodeficien-
cy at enrolment with a median baseline CD4 cell count of 98 cells/
mL (IQR 48–155). Patients that died were older and more likely to
be male have WHO stage 3 or 4 disease, lower baseline CD4 cell
counts and higher HIV viral loads (Table 1).
TB Diagnoses
Almost half of patients (47.0%) had a past history of TB and had
completed a course of anti-tuberculosis treatment before starting
ART (Table 1). At the time of ART initiation, 30% (n = 464) of
patients were receiving anti-tuberculosis treatment (prevalent TB).
Diagnoses of incident TB were made among 424 (27.5%) patients
during ART. In total there were 484 diagnoses of incident TB,
with 49 patients having 2 or more diagnoses of incident TB.
Overall, 73.6% of TB diagnoses were confirmed by culture.
Mortality Rates
208 deaths occurred during ART with an overall mortality rate
of 3.2 deaths/100 person-years (PY) (95% CI 2.79–3.66). A
majority of deaths (n = 124; 59.6%) occurred during the first year
of ART with a rate of 8.84 deaths/100 PY (95% CI 7.41–10.54).
The mortality rate decreased 4-fold in the second year of ART
(n = 26, 2.07 deaths/100 PY, 95% CI 7.41–10.54). Thereafter,
rates during years 2–3, 3–4, 4–5 and .5 years of ART decreased
to 1.67 (n = 19, 95% CI 1.06–2.62), 1.86 (n = 19, 95% CI 1.18–
2.91), 1.22 (n = 11, 95% CI 068–2.21) and 1.14 (n = 9, 95% CI
0.59–2.19) deaths/100 PY respectively.
Mortality rates during ART were substantially greater among
patients with prevalent TB at baseline compared to those who
were TB-free (4.84 versus 2.62 deaths/100 PY; p,0.001).
Similarly, mortality rates were almost double during person-time
accrued following incident TB compared to person-time without
incident TB (5.02 versus 2.79 deaths/100 PY; p,0.001). Mortal-
Figure 1. Patient enrolment in the antiretroviral treatment service and outcomes during follow-up.
doi:10.1371/journal.pone.0055824.g001
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ity rates calculated using only culture-confirmed incident TB cases
were similar to rates considering all TB diagnoses (4.53 deaths/
100 PY, 95% CI 3.45–6.12; p = 0.61).
Next, mortality rates stratified by time-updated CD4 cell counts
were calculated for the overall cohort and for person-time accrued
after diagnoses of incident TB (Table 2). Rates were highest
(22.87 deaths/100 PYs (95% CI 18.80–27.83) during person-time
accrued with CD4 cells counts ,100 cells/mL and decreased to
0.72 deaths/100 PYs (95% CI 0.42–1.20) during person-time
accrued with CD4 cell counts .500 cells/mL. Mortality rates
following a diagnosis of incident TB were also strongly associated
with time-updated CD4 cell counts (Table 2). Rates were 34.7
deaths/100 PYs (95% CI 23.4–51.3) during person-time accrued
with CD4 cells counts ,100 cells/mL, decreasing to 8.0 deaths/
100 PYs (95% CI 4.6–14.1) and 1.1 deaths/100 PYs (95% CI 0.4–
2.9) with CD4 cells counts 101–200 and .500 cells/mL,
respectively.
Risk Factors for Mortality
In unadjusted analyses, mortality was strongly associated with
baseline characteristics including lower CD4 cell counts, higher
viral load, increasing age, male gender, WHO stage 3 and 4
disease, past history of TB before ART initiation and prevalent TB
at ART initiation (Table 3). Shorter duration of ART, time-
updated viral load counts .1000 copies/ml, lower time-updated
CD4 cell counts and incident TB during ART were also strongly
associated with mortality. Person-time accrued at CD4 cell counts
,100 cells/mL had a 30 times greater risk of mortality compared
to person-time at CD4 cell counts .500 cells/mL (IRR 31.84;
95% CI 17.9–56.7; p,0.001).
Past history of TB was excluded from the multivariate analysis
due to a strong association with WHO stage, since pulmonary TB
is a stage 3 defining condition and extrapulmonary TB is a stage 4
defining condition. In multivariate analysis, time-updated CD4
cell counts remained the strongest risk factor for mortality
(Table 3). Prevalent TB at ART initiation was associated with a
1.7-fold increased mortality risk (IRR 1.67, 95% CI 1.23–2.25,
p = 0.001). Mortality risk during the first 6 months of ART in
those with prevalent TB at baseline was 2.3-fold higher (IRR 2.33,
95% CI 1.54–3.53) than that among those who did not have
prevalent TB. Mortality risk .6 months after starting ART was
not significantly increased among those with diagnoses of
Table 1. Characteristics for all patients and those alive at data censorship, lost to follow-up and died.
All patients
(n=1544) Alivec (n =811) Died (n=208)
Lost to follow-up
(n=318) p-valued
Mean age (years) [95% CI] 34 [33.6–34.4] 34.1 [33.6–34.6] 36.8 [35.5–38.1] 32.1 [31.3–33.0] ,0.001
Gender Male 462 (29.9) 236 (29.1) 85 (40.9) 93 (29.3) 0.006
WHO stage 1&2 305 (19.8) 184 (22.7) 14 (6.7) 67 (21.1)
3 861 (55.8) 451 (55.6) 108 (51.9) 186 (58.5) ,0.001
4 378 (24.5) 176 (21.7) 86 (41.4) 65 (20.4)
Baseline CD4 cell count
(cells/mL)
Median [IQR] 98 [48–155] 102 [51–158] 75 [22–136] 105 [53–168] ,0.001
Baseline viral load
(log10 copies/ml)
Median [IQR] 4.87 [4.46–5.26] 4.84 [4.45–5.25] 5.04 [4.63–2.58] 4.82 [4.37–5.79] ,0.001
Past history of TBa 725 (47.0) 368 (45.4) 131 (63.0) 133 (41.8) ,0.001
Prevalent TBb 464 (30.0) 212 (26.1) 82 (39.4) 103 (32.4) 0.099
Incident TB during ART 424 (27.5) 233 (28.7) 59 (28.4) 83 (26.1) 0.489
Data are numbers (%) unless otherwise stated. ART, antiretroviral therapy; TB, tuberculosis; IQR, interquartile range.
aincludes all TB episodes where anti-TB treatment was completed prior to ART enrolment.
bTB episodes where patients are taking anti-TB treatment at ART initiation.
calive at data censorship on 1st January 2011.
dcalculated comparing patients that died with those LTFU.
doi:10.1371/journal.pone.0055824.t001
Table 2. Overall mortality rates and mortality rates following incident TB during ART by CD4 cell strata.
Updated CD4 cell count
strata (cells/mL)
Overall
deaths
Overall PY
at risk
Overall mortality rate
per 100 PY (95% CI)
Deaths following
incident TBa
PY at risk following
incident TB
Mortality rate per
100 PYa (95% CI)
#100 100 437 22.9 (18.8–27.8) 25 72 34.7 (23.4–51.3)
101–200 47 982 4.8 (3.6–6.4) 12 149 8.0 (4.6–14.1)
201–300 24 1171 2.1 (1.4–3.1) 10 198 5.0 (2.7–9.4)
301–400 17 1138 1.5 (0.9–2.4) 4 208 1.9 (0.7–5.1)
401–500 7 968 0.7 (0.3–1.5) 4 183 2.2 (0.8–5.8)
.500 13 1810 0.7 (0.4–1.2) 4 365 1.1 (0.4–2.9)
ART, antiretroviral therapy; TB, tuberculosis PY, person-years; CI, confidence intervals.
aDuring person-time accrued following a diagnosis of incident TB.
doi:10.1371/journal.pone.0055824.t002
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prevalent TB compared to those without (IRR 1.33, 95% CI 0.90–
2.25, p = 0.141) (Figure 2).
After adjustment for other baseline and time-updated risk
factors, incident TB during ART was associated with a 2.7-fold
greater mortality risk compared to person-time with no TB
diagnoses (IRR 2.70, 95% CI 1.91–3.81, p,0.001). Incident TB
also showed a time-dependent effect on mortality risk in
multivariate models separately assessing person-time #6 months
and .6 months after a TB diagnosis. Compared to person-time
without incident TB, mortality risk #6 months after a TB
diagnosis was almost 4-fold higher (IRR 3.82, 95% CI 2.56–5.74).
Person-time .6 months after a diagnosis of incident TB was
associated with a smaller increase in mortality risk (IRR 1.90, 95%
CI 1.18–3.05) (Figure 2).
The adjusted mortality risk associated with diagnoses of
incident TB that were recurrent (IRR 2.97, 95% CI 2.07–4.27)
was higher than that associated with incident TB that was non-
recurrent (IRR 1.72, 95% CI 0.82–3.61) and again this risk was
time-dependent (Figure 2). Moreover, person-time following
multiple diagnoses (2 or more) of incident TB was associated
with a more than 8-fold increase in adjusted mortality risk
compared to person-time without a TB diagnoses (IRR 8.41,
95% CI 3.97–17.86) (Figure 2). In the multivariate analysis,
gender and duration of ART were no longer associated with
mortality.
Table 3. Unadjusted and multivariate analyses of risk factors for mortality during ART.
Unadjusted analysis Multivariate analysis
IRR 95% CI p-value IRR 95% CI p-value
Age at enrolmenta 1.04 1.02–1.06 ,0.001 1.04 1.02–1.06 ,0.001
Gender F 1 1
M 1.73 1.31–2.28 ,0.001 1.09 0.80–1.47 0.571
WHO stage at enrolment 1 & 2 1 1
3 2.88 1.65–5.02 ,0.001 1.77 0.97–3.19 ,0.001
4 5.50 3.13–9.67 3.41 1.87–6.24
Baseline CD4 cell count (cells/ml) $150 1 1
100–149 1.08 0.69–1.69 0.83 0.57–1.21
50–99 1.30 0.86–1.97 ,0.001 1.52 0.96–2.43 0.020
,50 2.04 1.39–2.99 1.67 1.04–2.65
Baseline viral load (log10 copies/ml) ,5 1 1
$5 1.64 1.24–2.17 0.001 1.34 1.01–1.79 0.040
Duration of ART (months) 0–12 1 1
12–24 0.23 0.15–0.36 0.61 0.38–0.98
24–36 0.19 0.12–0.31 0.62 0.36–1.07
36–48 0.21 0.13–0.34 ,0.001 0.66 0.37–1.16 0.123
48–60 0.14 0.07–0.26 0.51 0.26–1.02
.60 0.13 0.07–0.25 0.45 0.21–0.96
Updated CD4 cell count (cells/ml)d .500 1 1
401–500 1.00 0.40–2.52 0.93 0.37–2.35
301–400 2.08 1.01–4.28 1.77 0.84–3.71
201–300 2.85 1.45–5.60 ,0.001 1.87 0.90–3.87 ,0.001
101–200 6.66 3.60–12.31 2.98 1.44–6.20
0–100 31.84 17.87–56.74 10.41 4.69–23.14
Updated viral load (copies/ml)d ,1000 1 1
$1000 8.46 6.41–11.17 ,0.001 2.74 1.86–4.04 ,0.001
Past History of TB at baselineb No 1
Yes 1.87 1.41–2.47 ,0.001
Prevalent TB at baselinec No 1 1
Yes 1.85 1.40–2.44 ,0.001 1.67 1.23–2.25 0.001
Incident TB No 1 1
Yes 1.80 1.33–2.43 ,0.001 2.70 1.91–3.81 ,0.001
ART, antiretroviral therapy; TB, tuberculosis; IRR, incident rate ratio; CI, confidence interval. All p-values were calculated using the likelihood ratio test.
aAge is included as continuous variable, the IRR represents a 1 year increase in age.
bincludes all TB episodes where anti-TB treatment was completed prior to ART enrolment.
cTB episodes where patients are taking anti-TB treatment at ART initiation.
dCD4 cell counts and viral load are time-updated variables using serial measurements taken during ART.
doi:10.1371/journal.pone.0055824.t003
TB-Associated Mortality during ART
PLOS ONE | www.plosone.org 5 February 2013 | Volume 8 | Issue 2 | e55824
Loss to Follow-up
Among patients initiating ART, 318 were LTFU. Baseline
characteristics differed significantly between patients who died and
those that were LTFU (Table 1). Compared to those who died,
patients who were lost to follow-up were younger, more likely to be
female and have WHO stage 1 or 2 disease, higher baseline CD4
cell counts, lower HIV viral loads and fewer had a past history of
TB. A multivariate model constructed assuming all patients LTFU
were unascertained deaths still found prevalent TB (IRR 1.49,
95% CI 1.22–1.81) and incident TB (IRR 2.07, 95% CI 1.68–
2.56) to be independent risk factors for mortality.
Discussion
This study examined the impact of TB on mortality in an ART
cohort during long-term follow-up. The key findings are that, after
adjustment for other risk factors including time-updated CD4 cell
counts, person-time on ART in patients with prevalent and
incident TB remained independently associated with a 1.7 and
2.7-fold greater mortality risk, respectively, compared to person-
time in patients on ART without TB. This finding strongly
supports the view that TB is an important risk factor associated
with high mortality in ART programmes in sub-Saharan Africa
despite some studies suggesting the contrary [19]. There was also a
time-dependent relationship between TB and mortality risk, with
much higher adjusted mortality risk within the first 6 months of
ART in patients with baseline prevalent TB (IRR 2.3) and in the 6
months following diagnoses of incident TB (IRR 3.8). These
findings are similar to another study in South Africa which showed
mortality risk associated with TB diagnoses waned over time [16].
The strong time-dependent association between TB episodes and
increased mortality risk suggests that TB and mortality are causally
related, and that TB is not simply an epiphenomenon among this
highly immunocompromised patient population. Effective strate-
gies to diagnose, rapidly treat and prevent TB both prior to and
during ART urgently need to be implemented.
The huge burden of TB in this cohort is higher than in ART
services in other countries in sub-Saharan Africa but is similar to
others in South Africa [5,17,28–30]. The 2–3 fold increase in
mortality risk associated with such a common risk factor represents
a major challenge to ART programmes. The temporal distribution
of mortality risk and TB diagnosis further supports the association
between TB and death during ART. This could be hypothesized
as being a direct association with TB itself, or the result of other
Figure 2. Mortality incident risk ratios (IRR) associated with person-time accrued following prevalent (X) and incident (e)
tuberculosis (TB) compared to person-time with no TB diagnosis, adjusted for time-updated CD4 cell count and HIV viral load, and
other time-updated and baseline risk factors, stratified by timing after TB diagnosis, recurrent TB including all previous TB
diagnoses (m) or multiple diagnoses of incident TB (n).
doi:10.1371/journal.pone.0055824.g002
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associated factors such as drug co-toxicity, poor treatment
adherence due to high pill burden or TB immune reconstitution
disease. However, excellent immunovirological responses to
efavirenz-based ART have been documented in this cohort, drug
co-toxicity with this regimen is very low, and deaths from TB
immune reconstitution disease are infrequent (a recent meta-
analysis found only 3.2% of those with TB-associated immune
reconstitution disease died) [2,31–33]. Thus, the most plausible
explanation is that mortality was directly associated with active TB
disease. We were unable to estimate the prevalence and impact of
multi-drug resistance (MDR). Another more recent study in this
cohort has found MDR-TB in 5% of isolates and this may well be
another important factor [34].
A huge burden of TB was diagnosed under routine programme
conditions in this cohort, as previously described [2]. However,
more recent studies in this cohort have found that in patients with
no baseline TB diagnosis, systematic intensive culture-based
screening detects sputum culture-positive TB in 18% to 25% of
cases [34–36]. These findings support those of post-mortem studies
conducted in sub-Saharan Africa which have revealed a huge
burden of unascertained TB in HIV-positive patients [10–13].
Together these data suggest there remains a strong likelihood that
additional cases of TB remained unascertained in patients that
died during our study. Thus, we may have underestimated the
association between TB and mortality. Moreover, this study did
not account for deaths associated with prevalent TB that occurred
before ART was started. This may account for the weaker
association between mortality risk and prevalent TB compared to
that between mortality and incident TB. Another potential reason
for this difference is that, in addition to prevalent TB, multiple
other opportunistic infections occur at low CD4 cell counts and
may ‘compete’ as causes of death whereas during person-time at
high CD4 cell counts with long-term ART opportunistic infections
other than incident TB are uncommon.
Early detection of TB through active screening and rapid
initiation of treatment in diagnosed cases may potentially reduce
mortality [23]. New rapid diagnostics have the potential to greatly
expedite TB diagnosis compared to culture-based diagnosis that
was routinely used in this cohort. The Xpert MTB/RIF (Cepheid
Inc, Sunnyvale, CA, USA) is a simplified rapid molecular assay
and the Determine TB-LAM Ag (Alere, Waltham, MA, USA) is a
simple lateral-flow point-of-care assay that detects mycobacterial
lipoarabinomannan (LAM) in urine samples [34,35]. These both
offer the prospect of rapidly diagnosing TB, even in those with the
most advanced immunodeficiency and highest mortality risk
[37,38]. Prospective intervention studies are needed to determine
the impact of these assays on patient outcomes.
Once TB is diagnosed, patients need optimised case manage-
ment, including well integrated and patient-centred services
providing TB treatment, ART started in the course of TB
treatment (with optimal timing now defined by randomized
controlled trials) and trimethoprim-sulphamethoxazole prophy-
laxis [23,39]. Preventive measures are also required for those who
do not have TB. Prevalent TB can be prevented by initiation of
ART earlier in the course of HIV infection, thereby reducing time
accrued at lower CD4 cell counts and subsequent TB risk [22,40].
IPT can prevent TB prior to ART, and evidence from
observational studies also suggests an additive effect when
combined with ART [41,42]. Improving ART adherence and
access to second-line ART regimens should prevent TB and
reduce mortality by optimising immune recovery [43,44]. Further
data on the impact of drug resistance will also help inform
interventions and investments in drug-susceptibility testing and
new therapeutics.
Strengths of this study include the long median duration of
follow-up and high proportion of culture-confirmed TB diagnoses.
Routine monitoring of CD4 cell count and viral load 4-monthly
provides accurate information on time-updated immune response.
The observational design of this study has inherent limitations,
including the inability to establish a direct causal relationship
between TB and mortality, but the routine programmatic
conditions may improve the generalisability of the findings.
The distinction between prevalent and incident TB is blurred
and some prevalent disease missed at baseline screening may have
been classified as incident disease. Data on other incident AIDS or
non-AIDS defining illnesses were not available. If these occurred
around the time of TB diagnosis and were associated with death,
there may be an overestimation of the association between
mortality and tuberculosis. Patients classified as LTFU may
represent unascertained mortality and unascertained TB. Al-
though some studies have found high rates of mortality amongst
patients LTFU, earlier data from this cohort suggested relatively
low mortality amongst those LTFU [27,45]. Furthermore, the
present sensitivity analyses showed that even if all patients LTFU
were considered to be unascertained deaths, the association
between TB and mortality remained. This study was unable to
account for some important biological and social risk factors for
mortality, especially opportunistic infections with high case fatality
ratios such as cryptococcal meningitis and systemic sepsis, which
may have also caused an overestimation of the association between
TB and mortality [46]. However, most opportunistic infections are
strongly associated with CD4 cell count which was adjusted for.
Data on anaemia and body mass index (BMI), both strong
independent predictors of mortality [14], were not accounted for
in our multivariate model. This may be appropriate as both low
BMI and anaemia are strongly associated with TB and mycobac-
terial load, and thus are very likely to lie on the causal pathway
[37,47]. Cause of death could not be definitively determined for
most patients in this study. Few data exist on pathologically-
proven causes of ART-associated mortality from sub-Saharan
Africa. Such data are needed to further investigate the relationship
between TB and mortality in these settings.
In conclusion, our study shows a strong association between
prevalent and incident TB and mortality during ART. Strategies
to prevent TB prior to and during ART are needed, as are
diagnostic algorithms and new tools to rapidly identify cases and
initiate treatment. Such interventions are likely to represent key
interventions that are desperately needed to address the high
mortality rates in ART programmes in sub-Saharan Africa.
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